- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.70 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x N1F: N-(4-{2-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-oxoethyl}phenyl)acetamide(Non-covalent)
- 2 x ANP: PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER(Non-covalent)
ANP.2: 23 residues within 4Å:- Chain A: G.27, G.28, T.29, L.30, K.32, R.94, E.146, I.198, G.199, S.200, G.201, G.223, G.224, L.227, F.239, G.329, N.330, F.331, R.333
- Chain B: I.261
- Ligands: N1F.1, MG.3, EDO.5
25 PLIP interactions:25 interactions with chain A- Hydrogen bonds: A:G.28, A:T.29, A:T.29, A:L.30, A:K.32, A:R.94, A:G.199, A:S.200, A:S.200, A:G.201, A:G.223, A:E.240, A:N.330, A:N.330, A:F.331, A:R.333
- Water bridges: A:K.32, A:K.32, A:E.146, A:E.146, A:N.197, A:G.199, A:G.199
- Salt bridges: A:K.32
- pi-Stacking: A:F.239
ANP.7: 23 residues within 4Å:- Chain A: I.261
- Chain B: G.27, G.28, T.29, L.30, K.32, R.94, E.146, I.198, G.199, S.200, G.201, G.223, G.224, L.227, F.239, G.329, N.330, F.331, R.333
- Ligands: N1F.6, MG.8, EDO.10
23 PLIP interactions:23 interactions with chain B- Hydrogen bonds: B:G.28, B:T.29, B:L.30, B:K.32, B:R.94, B:G.199, B:S.200, B:S.200, B:G.201, B:G.223, B:E.240, B:N.330, B:N.330, B:F.331, B:R.333
- Water bridges: B:T.29, B:K.32, B:K.32, B:N.197, B:G.199, B:G.199
- Salt bridges: B:K.32
- pi-Stacking: B:F.239
- 2 x MG: MAGNESIUM ION(Non-functional Binders)
- 2 x ACT: ACETATE ION(Non-functional Binders)
ACT.4: 10 residues within 4Å:- Chain A: D.25, L.150, N.197, V.328, G.329, E.362, G.363, Y.364, F.365, G.366
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:V.328
- Hydrogen bonds: A:D.25, A:E.362, A:F.365, A:G.366
- Water bridges: A:A.367
ACT.9: 10 residues within 4Å:- Chain B: D.25, L.150, N.197, V.328, G.329, E.362, G.363, Y.364, F.365, G.366
5 PLIP interactions:5 interactions with chain B- Hydrophobic interactions: B:V.328
- Hydrogen bonds: B:E.362, B:F.365, B:G.366
- Water bridges: B:A.367
- 2 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.5: 6 residues within 4Å:- Chain A: L.30, T.69, I.71, R.94, F.95
- Ligands: ANP.2
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:R.94
EDO.10: 6 residues within 4Å:- Chain B: L.30, T.69, I.71, R.94, F.95
- Ligands: ANP.7
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:R.94
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Tangallapally, R. et al., Discovery of hPANK Activators with Improved Pharmacological Properties. To Be Published
- Release Date
- 2023-03-29
- Peptides
- Pantothenate kinase 3: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.70 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x N1F: N-(4-{2-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-oxoethyl}phenyl)acetamide(Non-covalent)
- 2 x ANP: PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER(Non-covalent)
- 2 x MG: MAGNESIUM ION(Non-functional Binders)
- 2 x ACT: ACETATE ION(Non-functional Binders)
- 2 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Tangallapally, R. et al., Discovery of hPANK Activators with Improved Pharmacological Properties. To Be Published
- Release Date
- 2023-03-29
- Peptides
- Pantothenate kinase 3: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A